BRAF and neoplasm: • Median OS after diagnosis of BrM and after SRS were favorable in patients with BRAF mutation and treated with SRS + BRAFi (23 months and 13, respectively, p < 0.01)• SRS local tumor control rate of 89.4% in the entire cohort• Local control rate improved in the patients treated with SRS + BRAFi compared to BRAF mutated patients without BRAFi treatment and wild-type patients